Cargando…
Diabetic Ketoacidosis Secondary to New Onset Type 1 Diabetes Mellitus Related to Pembrolizumab Therapy
Pembrolizumab is an immunoglobulin G4 (IgG4) monoclonal antibody used in the treatment of various types of cancers. Despite its efficacy, pembrolizumab does not specifically target cancer cells which often leads to common side effects seen in immunotherapies such as diarrhea, rash, fatigue, nausea,...
Autores principales: | Hernandez, Andrea, Zeidan, Bassem, Desai, Parth, Frunzi, Johnathan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957841/ https://www.ncbi.nlm.nih.gov/pubmed/33738153 http://dx.doi.org/10.7759/cureus.13302 |
Ejemplares similares
-
Adverse Side Effects: Empagliflozin-Related Acute Pancreatitis Case Report
por: Zeidan, Bassem S, et al.
Publicado: (2020) -
New-Onset Autoimmune Diabetes Mellitus Presenting As Diabetic Ketoacidosis in Association With Pembrolizumab Therapy and Long Term Follow-Up: Case Report
por: Pachpande, Vrushali, et al.
Publicado: (2022) -
Adrenal Crisis Secondary to Influenza and Tetanus Vaccination in an Adult Without Known Adrenal Insufficiency: A Case of Autoimmune Adrenalitis
por: Kamath, Shiwani, et al.
Publicado: (2021) -
Severe Hypercalcemia in an Adolescent with New-Onset Diabetes Mellitus and Diabetic Ketoacidosis
por: Gurnurkar, Shilpa, et al.
Publicado: (2020) -
Pembrolizumab-Induced Diabetic Ketoacidosis: A Review of Critical Care Case
por: Sankar, Keerthana, et al.
Publicado: (2021)